title: Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.
abstract: During recent years the MAO inhibitors have come to assume increasing importance in clinical practice. Attempts have been made to improve the tolerability of these substances by evolving a new generation of MAO inhibitors. Brofaromine, a newly developed MAO inhibitor of the second generation, is a selective, reversible, and short-acting MAO-A inhibitor. Under this drug, the dangerous "cheese effect" can be expected to occur only under extreme conditions, if at all. Clinical trials performed to date, including double-blind trials versus tranylcypromine and imipramine, have shown that brofaromine displays good antidepressive efficacy and good tolerability.
authors.affiliation: Department of Psychiatry, University Bonn, Germany.
authors.forename: H J
authors.initials: HJ
authors.lastname: Möller
authors.forename: G
authors.initials: G
authors.lastname: Wendt
authors.forename: P
authors.initials: P
authors.lastname: Waldmeier
mesh_terms: D000818:Animals; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine